Moderna (MRNA) Net Income towards Common Stockholders (2017 - 2026)

Moderna (MRNA) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$1.3 billion in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 38.31% year-over-year to -$1.3 billion in Q1 2026; TTM through Mar 2026 was -$3.2 billion, a 4.86% increase from a year earlier, with the FY2025 full-year figure at -$2.8 billion, up 20.75% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$1.3 billion, down from -$826.0 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for MRNA reached as high as $3.7 billion in Q1 2022 and fell as low as -$3.6 billion in Q3 2023.
• Historically, Net Income towards Common Stockholders has averaged -$239.9 million across 5 years, with a median of -$825.0 million in 2025.
• Across the five-year window, Net Income towards Common Stockholders jumped 199.51% in 2022 and slumped 1638.46% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $1.5 billion in 2022, then sank by 85.19% to $217.0 million in 2023, then tumbled by 616.13% to -$1.1 billion in 2024, then grew by 26.25% to -$826.0 million in 2025, then sank by 62.59% to -$1.3 billion in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$1.3 billion in Q1 2026, -$826.0 million in Q4 2025, and -$200.0 million in Q3 2025.